PA
MRTX

Perceptive Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Perceptive Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-719,103
Closed -$26M – 110
2023
Q2 		$26M Sell
719,103
-855,031
-54% -$35.2M 0.75% 42
2023
Q1 		$58.5M Sell
1,574,134
-617,291
-28% -$27.8M 1.73% 16
2022
Q4 		$99.3M Sell
2,191,425
-593,371
-21% -$38.4M 2.79% 8
2022
Q3 		$194M Sell
2,784,796
-82,067
-3% -$6.07M 5.64% 2
2022
Q2 		$192M Buy
2,866,863
+486,153
+20% +$30.9M 6.03% 3
2022
Q1 		$196M Sell
2,380,710
-903,073
-28% -$92.4M 3.92% 6
2021
Q4 		$482M Sell
3,283,783
-103,962
-3% -$16.1M 7.42% 2
2021
Q3 		$599M Buy
3,387,745
+201,847
+6% +$32.5M 8.71% 1
2021
Q2 		$515M Sell
3,185,898
-288,607
-8% -$46.3M 6.68% 1
2021
Q1 		$595M Sell
3,474,505
-219,011
-6% -$43.4M 7.53% 1
2020
Q4 		$811M Buy
3,693,516
+257,941
+8% +$55.8M 8.71% 1
2020
Q3 		$570M Buy
3,435,575
+664,525
+24% +$90.9M 8.33% 1
2020
Q2 		$316M Sell
2,771,050
-548,400
-17% -$53.2M 5.13% 5
2020
Q1 		$255M Buy
3,319,450
+116,044
+4% +$10.4M 6.65% 4
2019
Q4 		$413M Sell
3,203,406
-111,200
-3% -$10.7M 8.2% 2
2019
Q3 		$258M Buy
3,314,606
+415,000
+14% +$38.9M 6.96% 3
2019
Q2 		$299M Buy
2,899,606
+1,735,224
+149% +$135M 6.85% 3
2019
Q1 		$85.3M Buy
1,164,382
+1,038,507
+825% +$70.6M 2.41% 12
2018
Q4 		$5.25M Buy
+125,875
New +$5.02M 0.2% 65
2018
Q3 		– Sell
-713,191
Closed -$35.2M – 138
2018
Q2 		$35.2M Buy
713,191
+684,100
+2,352% +$25.8M 0.92% 34
2018
Q1 		$893K Hold
29,091
– – 0.03% 110
2017
Q4 		$531K Buy
+29,091
New +$451K 0.02% 120
2017
Q1 		– Sell
-521
Closed -$2K – 211
2016
Q4 		$2K Buy
+521
New +$2.83K ﹤0.01% 177
2016
Q2 		– Sell
-273,000
Closed -$5.84M – 207
2016
Q1 		$5.84M Buy
+273,000
New +$6.1M 0.51% 49

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors's MRTX Position: Q3 2023 in Review

Perceptive Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 719,103 shares — an estimated $26M sold.

Perceptive Advisors first reported a position in MRTX in Q1 2016 and held it in 24 quarters. The position peaked at $811M in Q4 2020. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Perceptive Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Perceptive Advisors sold 719,103 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $26M.
  • Perceptive Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2016 and held it in 24 quarters.
  • Perceptive Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $811M in Q4 2020.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.